Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Dna X (SONM) Operating Expenses (2018 - 2025)

Dna X filings provide 8 years of Operating Expenses readings, the most recent being -$15.7 million for Q4 2025.

  • On a quarterly basis, Operating Expenses rose 15.43% to -$15.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $5.4 million, a 74.39% increase, with the full-year FY2025 number at $5.4 million, up 74.39% from a year prior.
  • Operating Expenses hit -$15.7 million in Q4 2025 for Dna X, down from $5.8 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $12.5 million in Q3 2021 to a low of -$18.5 million in Q4 2024.
  • Median Operating Expenses over the past 5 years was $6.5 million (2023), compared with a mean of $4.9 million.
  • The widest YoY moves for Operating Expenses: up 156.56% in 2024, down 390.79% in 2024.
  • Dna X's Operating Expenses stood at $11.3 million in 2021, then crashed by 55.66% to $5.0 million in 2022, then grew by 27.73% to $6.4 million in 2023, then plummeted by 390.79% to -$18.5 million in 2024, then increased by 15.43% to -$15.7 million in 2025.
  • The last three reported values for Operating Expenses were -$15.7 million (Q4 2025), $5.8 million (Q3 2025), and $7.6 million (Q2 2025) per Business Quant data.